Karo Bio AB To Be Awarded 1 Msek From Vinnova
3/17/2014 9:00:42 AM
STOCKHOLM, March 17, 2014 - Karo Bio AB (publ) will be awarded 1 million SEK
from Vinnova for the preclinical development of an ER-beta agonist for the
treatment of multiple cancers. The grant is awarded through the Forska & Väx program to finance toxicity and
safety pharmacology studies of an ERbeta agonist. In previous studies, the
compound has been shown to significantly reduce tumor size in preclinical models
of mesothelioma and other types of cancer with poor prognosis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by